Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1975 Feb;7(2):146–152. doi: 10.1128/aac.7.2.146

Bacteriological Studies with Morphine-Like Narcotics: Relevance to Narcotic Actions in Mammals?

Alan D Wolfe 1, John G Olenick 1, Fred E Hahn 1
PMCID: PMC429094  PMID: 1094948

Abstract

A search for active bacterial growth inhibitors among seven highly potent morphine-like narcotics revealed that NIH 7591 and etorphine inhibited the rates of growth of Escherichia coli by 50% at 1.9 × 10−4 M. Bacterial cultures escaped from growth inhibition by NIH 7591 after times which were proportional to the drug concentrations and inversely proportional to the initial bacterial densities. Populations of E. coli could adapt to resist and cross-resist growth inhibitions by NIH 7591 and phenazocine. Resistance was lost after growth in drug-free medium for a few doubling times. The agonist-antagonist pair, etorphine and diprenorphine, inhibited growth of E. coli additively without any indication of antagonism. Actions of narcotics in bacteria is considered a theme in its own right.

Full text

PDF
146

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bentley K. W., Hardy D. G. Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine. J Am Chem Soc. 1967 Jun 21;89(13):3281–3292. doi: 10.1021/ja00989a032. [DOI] [PubMed] [Google Scholar]
  2. Blane G. F., Dugdall D. Interactions of narcotic antagonists and antagonist-analgesics. J Pharm Pharmacol. 1968 Jul;20(7):547–552. doi: 10.1111/j.2042-7158.1968.tb09803.x. [DOI] [PubMed] [Google Scholar]
  3. Boquet P. L., Devynck M. A., Monnier C., Fromageot P. Inhibition of stable RNA synthesis by levallorphan in Escherichia coli. Implication of compounds MS I and MS II. Eur J Biochem. 1973 Dec 3;40(1):31–42. doi: 10.1111/j.1432-1033.1973.tb03166.x. [DOI] [PubMed] [Google Scholar]
  4. Boquet P. L., Devynvk M. A., Fromageot P. Involvement of the RC locus in RNA synthesis inhibition by levallorphan in E. coli. FEBS Lett. 1971 Mar 22;13(5):279–281. doi: 10.1016/0014-5793(71)80240-5. [DOI] [PubMed] [Google Scholar]
  5. Boquet P., Devynck M., Aurelle H., Fromageot P. On the bactericidal action of levallorphan. Irreversible alterations of the plasmic membrane. Eur J Biochem. 1971 Aug 25;21(4):536–541. doi: 10.1111/j.1432-1033.1971.tb01499.x. [DOI] [PubMed] [Google Scholar]
  6. Connamacher R. H., Mandel H. G., Hahn F. E. Adaptation of populations of Bacillus cereus to tetracycline. Mol Pharmacol. 1967 Nov;3(6):586–594. [PubMed] [Google Scholar]
  7. Devynck M. A., Boquet P. L., Fromageot P. On the mode of action of levallorphan on Escherichia coli: effects on cellular magnesium. Mol Pharmacol. 1971 Nov;7(6):605–610. [PubMed] [Google Scholar]
  8. ELION G. B., SINGER S., HITCHINGS G. H. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem. 1954 Jun;208(2):477–488. [PubMed] [Google Scholar]
  9. Greene R., Magasanik B. The mode of action of levallorphan as an inhibitor of cell growth. Mol Pharmacol. 1967 Sep;3(5):453–472. [PubMed] [Google Scholar]
  10. Harshman R. B., Yamazaki H. Levallorphan-induced accumulation of ppGpp in Escherichia coli. Biochemistry. 1972 Apr 11;11(8):1363–1366. doi: 10.1021/bi00758a006. [DOI] [PubMed] [Google Scholar]
  11. Knape H., Boquet P. L., Röschenthaler R. Inhibition of amino acid transport in Escherichia coli cells and its cell membranes. FEBS Lett. 1972 Jan 1;19(4):311–314. doi: 10.1016/0014-5793(72)80068-1. [DOI] [PubMed] [Google Scholar]
  12. LOEWE S. Antagonisms and antagonists. Pharmacol Rev. 1957 Jun;9(2):237–242. [PubMed] [Google Scholar]
  13. Lowney L. I., Schulz K., Lowery P. J., Goldstein A. Partial purification of an opiate receptor from mouse brain. Science. 1974 Feb 22;183(4126):749–753. doi: 10.1126/science.183.4126.749. [DOI] [PubMed] [Google Scholar]
  14. Löser R., Boquet P. L., Röschenthaler R. Inhibition of R-factor transfer by levallorphan. Biochem Biophys Res Commun. 1971 Oct 1;45(1):204–211. doi: 10.1016/0006-291x(71)90070-2. [DOI] [PubMed] [Google Scholar]
  15. MELLETT L. B., WOODS L. A. ANALGESIA AND ADDICTION. Fortschr Arzneimittelforsch. 1963;5:155–267. doi: 10.1007/978-3-0348-7047-4_2. [DOI] [PubMed] [Google Scholar]
  16. MILLER J. W., ELLIOTT H. W. Rat tissue levels of carbon-14 labeled analgetics as related to pharmacological activity. J Pharmacol Exp Ther. 1955 Mar;113(3):283–291. [PubMed] [Google Scholar]
  17. MOYED H. S. Interference with feedback control of enzyme activity. Cold Spring Harb Symp Quant Biol. 1961;26:323–329. doi: 10.1101/sqb.1961.026.01.039. [DOI] [PubMed] [Google Scholar]
  18. Raab C., Röschenthaler R. Inhibition of adsorption and replication of the RNA-phage MS-2 in Escherichia coli C 3000 by levallorphan. Biochem Biophys Res Commun. 1970 Dec 24;41(6):1429–1436. doi: 10.1016/0006-291x(70)90546-2. [DOI] [PubMed] [Google Scholar]
  19. Rang H. P. Drug receptors and their function. Nature. 1971 May 14;231(5298):91–96. doi: 10.1038/231091a0. [DOI] [PubMed] [Google Scholar]
  20. SIMON E. J. INHIBITION OF BACTERIAL GROWTH BY DRUGS OF THE MORPHINE SERIES. Science. 1964 May 1;144(3618):543–544. doi: 10.1126/science.144.3618.543. [DOI] [PubMed] [Google Scholar]
  21. SIMON E. J., VANPRAAG D. INHIBITION OF RNA SYNTHESIS IN ESCHERICHIA COLI BY LEVORPHANOL. Proc Natl Acad Sci U S A. 1964 May;51:877–883. doi: 10.1073/pnas.51.5.877. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Simon E. J., Cohen S. S., Raina A. Polyamines and inhibition of RNA synthesis in E. coli by levorphanol. Biochem Biophys Res Commun. 1966 Aug 12;24(3):482–488. doi: 10.1016/0006-291x(66)90187-2. [DOI] [PubMed] [Google Scholar]
  23. Simon E. J., Schapira L., Wurster N. Effect of levorphanol on putrescine transport in Escherichia coli. Mol Pharmacol. 1970 Nov;6(6):577–587. [PubMed] [Google Scholar]
  24. WAY E. L., ADLER T. K. The biological disposition of morphine and its surrogates. I. Bull World Health Organ. 1961;25:227–262. [PMC free article] [PubMed] [Google Scholar]
  25. WEAVER J. R., PATTEE P. A. INDUCIBLE RESISTANCE TO ERYTHROMYCIN IN STAPHYLOCOCCUS AUREUS. J Bacteriol. 1964 Sep;88:574–580. doi: 10.1128/jb.88.3.574-580.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wolfe A. D., Cook T. M., Hahn F. E. Antibacterial nitroacridine, Nitroakridin 3582: effects on bacterial growth and macromolecular biosynthesis in vivo. J Bacteriol. 1971 Oct;108(1):320–327. doi: 10.1128/jb.108.1.320-327.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wurster N., Elsbach P., Rand J., Simon E. J. Effects of levorphanol on phospholipid metabolism and composition in Escherichia coli. Biochim Biophys Acta. 1971 Nov 5;248(2):282–292. doi: 10.1016/0005-2760(71)90016-6. [DOI] [PubMed] [Google Scholar]
  28. Zimmerman A. M. Sensitivity of Amoeba proteus to morphine and N-allylnormorphine. A pressure study. J Protozool. 1967 Aug;14(3):451–455. doi: 10.1111/j.1550-7408.1967.tb02025.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES